Intellia Therapeutics, INC. (NTLA) — SEC Filings

Overview

Intellia Therapeutics, INC. (NTLA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Intellia Therapeutics, Inc. (NTLA) reported a net loss of $101.3 million for the three months ended September 30, 2025, an improvement from the $135.7 million net loss in the same period of 2024. Collaboration revenue increased to $13.8 million in Q3 2025 from $9.1 million in Q3 2024. Research and d

Sentiment Summary

Across 35 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 32 neutral, 1 mixed. The dominant filing sentiment for Intellia Therapeutics, INC. is neutral.

Filing Type Overview

Intellia Therapeutics, INC. (NTLA) has filed 22 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 4 SC 13G/A with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (35)

• 8-K Filing — 8-K · Nov 10, 2025
• Intellia Narrows Losses, Boosts Revenue on R&D Cuts — 10-Q · Nov 6, 2025 Risk: high
  Intellia Therapeutics, Inc. (NTLA) reported a net loss of $101.3 million for the three months ended September 30, 2025, an improvement from the $135.7 million n
• Intellia Therapeutics Files 8-K — 8-K · Oct 29, 2025 Risk: low
  Intellia Therapeutics, Inc. filed an 8-K on October 29, 2025, reporting an event under "Other Events." The filing does not contain specific details about the ev
• Intellia Therapeutics Files 8-K — 8-K · Oct 27, 2025 Risk: low
  Intellia Therapeutics, Inc. filed an 8-K on October 27, 2025, reporting on various events. The filing includes information related to Regulation FD Disclosure,
• Intellia Therapeutics Files 8-K — 8-K · Sep 25, 2025 Risk: low
  On September 25, 2025, Intellia Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures, other events, and financial sta
• Intellia's Q2 Loss Widens on Soaring R&D, Revenue Dips 24% — 10-Q · Aug 7, 2025 Risk: high
  Intellia Therapeutics reported a net loss of $120.3 million for the second quarter of 2025, a significant increase from the $105.1 million net loss in the same
• Intellia Therapeutics Files 8-K — 8-K · Jun 16, 2025 Risk: low
  Intellia Therapeutics, Inc. filed an 8-K on June 16, 2025, reporting events as of June 15, 2025. The filing primarily concerns Regulation FD disclosures, other
• Intellia Therapeutics Files 8-K on Officer/Director Changes & Shareholder Votes — 8-K · Jun 12, 2025 Risk: medium
  Intellia Therapeutics, Inc. filed an 8-K on June 12, 2025, reporting events that occurred on June 11, 2025. The filing includes information regarding the depart
• Intellia Therapeutics Files 8-K — 8-K · May 28, 2025 Risk: low
  Intellia Therapeutics, Inc. filed an 8-K on May 28, 2025, to report on events that occurred on the same date. The filing indicates it is for a Regulation FD Dis
• Intellia Therapeutics Files 8-K — 8-K · May 19, 2025 Risk: low
  Intellia Therapeutics, Inc. filed an 8-K on May 19, 2025, reporting events as of May 18, 2025. The filing includes information related to Regulation FD Disclosu
• Intellia Therapeutics Files Q1 2025 10-Q — 10-Q · May 8, 2025 Risk: medium
  Intellia Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, located at 40 Erie Street, Suite 130, Cambridge, MA, reported on i
• Intellia Therapeutics Executive Compensation Details Released — DEF 14A · Apr 30, 2025 Risk: medium
  Intellia Therapeutics, Inc. filed a DEF 14A on April 30, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing include
• Intellia Therapeutics Files 8-K with Bylaw Amendments — 8-K · Apr 7, 2025 Risk: low
  Intellia Therapeutics, Inc. filed an 8-K on April 7, 2025, reporting an event on April 3, 2025. The filing indicates amendments to its articles of incorporation
• Intellia Therapeutics Files 2024 10-K — 10-K · Feb 27, 2025 Risk: medium
  Intellia Therapeutics, Inc. filed its 2024 10-K on February 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on in vitro an
• Intellia Therapeutics Enters Material Definitive Agreement — 8-K · Feb 21, 2025 Risk: medium
  Intellia Therapeutics, Inc. entered into a material definitive agreement on February 18, 2025. This agreement creates a direct financial obligation or an obliga
• Intellia Therapeutics Files 8-K — 8-K · Jan 10, 2025 Risk: medium
  Intellia Therapeutics, Inc. filed an 8-K on January 10, 2025, reporting on events as of January 9, 2025. The filing covers results of operations, costs associat
• Intellia Therapeutics Files 8-K — 8-K · Nov 18, 2024 Risk: low
  Intellia Therapeutics, Inc. filed an 8-K on November 18, 2024, reporting on events that occurred on November 16, 2024. The filing is categorized under Regulatio
• Intellia Therapeutics Files 8-K for Financials — 8-K · Nov 7, 2024 Risk: low
  Intellia Therapeutics, Inc. filed an 8-K on November 7, 2024, to report on its results of operations and financial condition, as well as to file financial state
• Intellia Therapeutics Partners with Regeneron for Autoimmune Disease Therapy — 8-K · Oct 25, 2024 Risk: medium
  Intellia Therapeutics, Inc. announced on October 24, 2024, that it has entered into a clinical trial collaboration and supply agreement with Regeneron Pharmaceu
• Intellia Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 8, 2024 Risk: medium
  Intellia Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial condition and business operations. Key fin
• Intellia Therapeutics Announces Executive Appointments — 8-K · Jun 26, 2024 Risk: medium
  Intellia Therapeutics, Inc. announced on June 21, 2024, changes in its board of directors and executive compensation. Specifically, Dr. John Leonard has been ap
• Intellia Therapeutics Appoints New Officers, Adjusts Compensation — 8-K · Jun 14, 2024 Risk: medium
  Intellia Therapeutics, Inc. announced on June 12, 2024, changes in its board of directors and executive compensation. Specifically, Dr. Laura Hansen was appoint
• Intellia Therapeutics Files 8-K — 8-K · Jun 13, 2024 Risk: low
  Intellia Therapeutics, Inc. filed an 8-K on June 12, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filing det
• Intellia Therapeutics Reports First Quarter 2024 Financial Results — 10-Q · May 9, 2024 Risk: medium
  Intellia Therapeutics, Inc. (NTLA) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Intellia Therapeutics, Inc. filed a 10-Q for the period ending M
• Intellia Therapeutics Announces 2024 Annual Meeting of Stockholders on June 12 — DEF 14A · Apr 29, 2024 Risk: low
  Intellia Therapeutics, Inc. (NTLA) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. The 2024 Annual Meeting of Stockholders for Intellia Therap
• Intellia Therapeutics Announces Executive and Board Changes — 8-K · Apr 15, 2024 Risk: medium
  Intellia Therapeutics, Inc. announced on April 10, 2024, changes in its executive and board leadership. Dr. John Leonard has been appointed as the new Chief Exe
• Intellia Therapeutics Terminates Deal with Regeneron — 8-K · Mar 22, 2024 Risk: medium
  Intellia Therapeutics, Inc. announced on March 19, 2024, the termination of its material definitive agreement with Regeneron Pharmaceuticals, Inc. This terminat
• Intellia Therapeutics Enters Material Definitive Agreement — 8-K · Feb 23, 2024 Risk: medium
  Intellia Therapeutics, Inc. filed an 8-K on February 23, 2024, to report the entry into a material definitive agreement. The filing indicates that the earliest
• Intellia Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 22, 2024 Risk: medium
  Intellia Therapeutics, Inc. (NTLA) filed a Annual Report (10-K) with the SEC on February 22, 2024. Intellia Therapeutics, Inc. filed its 2023 Form 10-K on Febru
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Intellia Therapeutics Files Routine 8-K on Jan 31 Event — 8-K · Feb 1, 2024
  Intellia Therapeutics, Inc. filed an 8-K on February 1, 2024, reporting an event that occurred on January 31, 2024. This filing is a routine disclosure, specifi
• ARK Investment Management Holds 12.9% Stake in Intellia Therapeutics — SC 13G/A · Jan 29, 2024
  ARK Investment Management LLC, led by Cathie Wood, filed an amended SC 13G/A on January 29, 2024, revealing a significant stake in Intellia Therapeutics, Inc. A
• State Street Corp. Updates Passive Stake in Intellia Therapeutics — SC 13G/A · Jan 24, 2024
  State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 24, 2024, indicating its ownership of Intellia Therapeutics Inc. c
• BlackRock Amends Intellia Therapeutics Stake, Signals Confidence — SC 13G/A · Jan 8, 2024
  BlackRock, Inc. filed an amended SC 13G/A on January 8, 2024, indicating its ownership of Intellia Therapeutics, Inc. Common Stock as of December 31, 2023. This
• Intellia Therapeutics Files 8-K on Financial Condition, Other Events — 8-K · Jan 4, 2024
  Intellia Therapeutics, Inc. filed an 8-K on January 4, 2024, to report on its 'Results of Operations and Financial Condition,' 'Regulation FD Disclosure,' and '

Related Companies

CRSP · EDIT · BEAM · REGN

Frequently Asked Questions